Related Experiment Videos

Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure

Masayuki Yamaji1, Takayoshi Tsutamoto, Toshinari Tanaka

  • 1Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Japan.

Circulation Journal : Official Journal of the Japanese Circulation Society
|April 16, 2009
PubMed

Insights

Carvedilol treatment in chronic heart failure (CHF) patients significantly lowered plasma adiponectin levels. This reduction in adiponectin correlated with improved left ventricular ejection fraction (LVEF), suggesting a potential therapeutic benefit.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • High plasma adiponectin is linked to poor prognosis in chronic heart failure (CHF).
  • ACE inhibitors and ARBs may increase adiponectin, but beta-blocker effects are unknown.

Purpose of the Study:

  • To investigate the effect of carvedilol on plasma adiponectin in CHF patients.
  • To explore the relationship between adiponectin changes and clinical outcomes.

Main Methods:

  • 44 CHF patients received carvedilol for 6 months.
  • Measurements included hemodynamic parameters, echocardiography, and plasma adiponectin, BNP, and norepinephrine levels.
  • Multivariable analyses assessed predictors of adiponectin decrease and its correlation with LVEF improvement.

Main Results:

  • Carvedilol significantly decreased plasma adiponectin (15.8 to 11.0 microg/ml, P<0.0001).
  • BNP and norepinephrine levels also decreased, while LVEF increased.
  • Pre-treatment adiponectin predicted the magnitude of decrease; this decrease correlated with LVEF improvement.

Conclusions:

  • Carvedilol reduces plasma adiponectin concentration in CHF patients.
  • The observed decrease in adiponectin is associated with improved LVEF post-treatment.
Abstract

Related Concept Videos

Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.